From: Treatment pathways and associated costs of metastatic colorectal cancer in Greece
 | RAS mutated | BRAF mutated | RAS/BRAF WT left | RAS/BRAF WT right | MSI-H dMMR | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1st line | 2nd line | 3rd line | 1st line | 2nd line | 3rd line | 1st line | 2nd line | 3rd line | 1st line | 2nd line | 3rd line | 2nd line | 3rd line | |
Folfiri | 5 | 10 | 10 | 10 | 20 | Â | Â | Â | 20 | 5 | Â | Â | Â | 70 |
Folfiri & Cetuximab | Â | Â | Â | Â | Â | Â | 15 | 5 | 10 | Â | 15 | 10 | Â | Â |
Folfiri & Panitumumab | Â | Â | Â | Â | Â | Â | 20 | 5 | Â | Â | 25 | 10 | Â | Â |
Folfiri & Bevacizumab | 15 | 20 | Â | 15 | 25 | Â | 10 | 30 | Â | 20 | 10 | Â | Â | Â |
Folfiri & Aflibercept | Â | 15 | Â | Â | 10 | Â | Â | 10 | Â | Â | 10 | Â | Â | Â |
Folfox | 5 | 5 | 5 | 10 | Â | Â | Â | Â | Â | Â | 10 | Â | Â | Â |
Folfox & Cetuximab | Â | Â | Â | Â | 10 | Â | 15 | 5 | Â | Â | Â | Â | Â | Â |
Folfox & Panitumumab | Â | Â | Â | Â | Â | Â | 20 | 5 | Â | Â | Â | Â | Â | Â |
Folfox & Bevacizumab | 35 | 15 | Â | 5 | Â | Â | 10 | 28 | Â | 10 | 10 | Â | Â | Â |
Folfoxiri | 3 | Â | Â | 20 | Â | Â | Â | Â | Â | 20 | Â | Â | Â | Â |
Folfoxiri & Panitumumab | Â | Â | Â | Â | Â | Â | Â | Â | Â | 5 | Â | Â | Â | Â |
Folfoxiri & Bevacizumab | 12 | Â | Â | 30 | Â | Â | Â | Â | Â | 30 | Â | Â | Â | Â |
Capecitabine | Â | Â | 5 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Capecitabine and Oxaliplatin (CapOX) | 3 | 10 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
CapOX & Bevacizumab | 12 | 10 | Â | 10 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Capecitabine & Bevacizumab | 10 | 10 | Â | Â | Â | Â | 10 | 10 | 10 | 10 | 10 | 10 | Â | Â |
Tas102 | Â | Â | 50 | Â | Â | 40 | Â | Â | 40 | Â | Â | 40 | Â | Â |
Regorafenib | Â | Â | 30 | Â | Â | 10 | Â | Â | 10 | Â | Â | 10 | Â | Â |
Encorafenib & Cetuximab | Â | Â | Â | Â | 25 | 50 | Â | Â | Â | Â | Â | Â | Â | Â |
Cetuximab | Â | Â | Â | Â | Â | Â | Â | Â | 10 | Â | Â | 10 | Â | Â |
Panitumumab | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | 10 | Â | Â |
Immunotherapies | Â | 5 | Â | Â | 10 | Â | Â | 2 | Â | Â | 10 | Â | 100 | 30 |
Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |